The exclusion of people living with HIV (PLWH) from clinical trials in lymphoma
Authors:
Open Access
- 27 August 2015
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 113 (6) , 861-863
Abstract
The prognosis of non-Hodgkin lymphoma and Hodgkin lymphoma is not affected by HIV serostatus, yet people living with HIV (PLWH) are frequently excluded from clinical trials in lymphoma. The UK NIHR Clinical Research Network Study Portfolio website was used to identify all the open clinical trials in lymphoma in the United Kingdom in January 2015. Trials that excluded PLWH were further investigated to evaluate if the exclusion was justified by scientific evidence. We identified 56 multicentre open clinical trials in lymphoma including 46 interventional trials. People living with HIV were excluded from 32 interventional trials (70%). We identified a biologically valid reason (a potential increased risk of greater immunosuppression) for excluding PLWH from one trial and possibly for one optional arm in another study. There was no scientific or safety justification for excluding PLWH from most lymphoma clinical trials included on the NIHR portfolio. A clear justification for excluding PLWH was not offered in the available protocols. The exclusion of PLWH should be explicitly justified on scientific grounds in protocols to minimise stigmatisation.Keywords
This publication has 10 references indexed in Scilit:
- Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical DosingPLOS Pathogens, 2014
- HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART eraAIDS, 2014
- British HIV Association guidelines for HIV‐associated malignancies 2014HIV Medicine, 2014
- HIV Status Does Not Influence Outcome in Patients With Classical Hodgkin Lymphoma Treated With Chemotherapy Using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the Highly Active Antiretroviral Therapy EraJournal of Clinical Oncology, 2012
- Cancer risk in people infected with human immunodeficiency virus in the United StatesInternational Journal of Cancer, 2008
- Including Persons With HIV Infection in Cancer Clinical TrialsJournal of Clinical Oncology, 2008
- Monocarboxylate transporter MCT1 is a target for immunosuppressionNature Chemical Biology, 2005
- Incidence of Non–AIDS-Defining Cancers Before and During the Highly Active Antiretroviral Therapy Era in a Cohort of Human Immunodeficiency Virus–Infected PatientsJournal of Clinical Oncology, 2003
- Risk of Cancer in Patients with HIV DiseaseInternational Journal of STD & AIDS, 1999
- Non-Hodgkin's lymphoma among people with AIDS: Incidence, presentation and public health burdenInternational Journal of Cancer, 1997